Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting

A. V. Stepanov; Степанов A. В.; A. A. Belogurov; Белогуров A. A.; P. Kothapalli; Kothapalli P.; O. G. Shamborant; Шамбoрант O. Г.; V. D. Knorre; Кнорре В. Д.; G. B. Telegin; Телегин Г. Б.; A. A. Ovsepyan; Овсепян A. A.; N. A Ponomarenko; Пономаренко Н. A.; S. M. Deyev; Деев С. M.; S. V. Kaveri; Kaveri S. V.; A. G. Gabibov; Габибов A. Г.

doi:10.32607/20758251-2015-7-2-74-79

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting

Authors: Stepanov A.V.¹^,2, Belogurov A.A.¹^,2^,3, Kothapalli P.⁴, Shamborant O.G.¹, Knorre V.D.¹, Telegin G.B.¹, Ovsepyan A.A.¹, Ponomarenko N.A¹, Deyev S.M.¹, Kaveri S.V.⁴, Gabibov A.G.¹^,2^,3
Affiliations:
1. M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry
2. Kazan Federal University
3. Institute of Gene Biology, Russian Academy of Sciences
4. Centre de Recherche des Cordeliers, Université Pierre et Marie Curie
Issue: Vol 7, No 2 (2015)
Pages: 74-79
Section: Research Articles
Submitted: 17.01.2020
Published: 15.06.2015
URL: https://actanaturae.ru/2075-8251/article/view/10502
DOI: https://doi.org/10.32607/20758251-2015-7-2-74-79
ID: 10502

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders.

Keywords

multiple sclerosis, autoantigens, B cells, immunoglobulins, immunotoxins

References

Nylander A., Hafler D.A. // J. Clin. Invest. 2012. V. 122. P. 1180-1188.
Kingwell E., Marriott J.J., Jette N., Pringsheim T., Makhani N., Morrow S.A., Fisk J.D., Evans C., Beland S.G., Kulaga S. // BMC Neurol. 2013. V. 13. P. 128.
Ransohoff R.M., Hafler D.A., Lucchinetti C.F. // Nat. Rev. Neurol. 2015. V. 11. P. 134-142.
Sorensen P.S. // Curr. Opin. Neurol. 2014. V. 27. P. 246-259.
Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. // Nat. Rev. Neurol. 2012. V. 8. P. 613-623.
Marino E., Grey S.T. // Autoimmunity. 2012. V. 45. P. 377-387.
Arkfeld D.G. // Rheumatol. Int. 2008. V. 28. P. 205-215.
Wang M., Fowler N., Wagner-Bartak N., Feng L., Romaguera J., Neelapu S.S., Hagemeister F., Fanale M., Oki Y., Pro B. // Leukemia. 2013. V. 27. P. 1902-1909.
Ransohoff R.M., Zamvil S.S. // Neurotherapeutics. 2007. V. 4. P. 569-570.
Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. // J. Neuroimmunol. 2006. V. 180. P. 63-70.
Deyev S.M., Lebedenko E.N. // Acta Naturae. 2009. No. 1. P. 32-50.
Deyev S.M., Lebedenko E.N., Petrovskaya L.E., Dolgikh D.A., Gabibov A.G., Kirpichnikov M.P. // Russian chemical reviews. 2015. V. 84. No. 1. P. 1-26.
Castillo-Trivino T., Braithwaite D., Bacchetti P., Waubant E. // PLoS One. 2013. V. 8. P. e66308.
Sela M., Mozes E. // Proc. Natl. Acad. Sci. USA. 2004. V. 101. P. 14586-14592.
Stepanov A.V., Belogurov A.A. Jr., Ponomarenko N.A., Stremovskiy O.A., Kozlov L.V., Bichucher A.M., Dmitriev S.E., Smirnov I.V., Shamborant O.G., Balabashin D.S., et al. // PLoS One. 2011. V. 6 (6). P. e20991.
Zocher M., Baeuerle PA, Dreier T., Iglesias A. // Int Immunol. 2003. V.15 (7). P. 789-796.
Johnson A.B., Dal Canto M.C. // Nature. 1976. V. 264. P. 453-454.
Abramsky O., Lisak R.P., Silberberg D.H., Pleasure D.E. // New Engl. J. Med. 1978. V. 298. P. 743.
Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov A.A. Jr., Kurkova I.N., Petrenko A.G., Telegin G.B., Suchkov S.V., Kiselev S.L., Lagarkova M.A., et al. // Proc. Natl. Acad. Sci. USA. 2006. V. 103. № 2. P. 281-286.
Miller S.D., Karpus W.J., Davidson T.S. // Curr. Protoc. Immunol. 2010. Ch. 15. V. 15. P. 11.
Stromnes I.M., Goverman J.M. // Nat. Protoc. 2006. V. 1. P. 1810-1819.
Belogurov A.A. Jr., Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., Suchkov S.V., Kotov S.V., Alehin A.I., Avalle B., et al. // J. Immunol. 2008. V. 180. P. 1258-1267.
Yasuda T., Tsumita T., Nagai Y., Mitsuzawa E., Ohtani S. // Japan J. Exp. Med. 1975. V. 45. P. 423-427.
Sela M., Teitelbaum D. // Expert Opin. Pharmacother. 2001. V. 2. P. 1149-1165.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting

Full Text

Abstract

Keywords

About the authors

References

Supplementary files

This website uses cookies